Clinical Trial Update: Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for VXB-251, a trivalent vaccine targeting RSV, human metapneumovirus, and parainfluenza virus type 3, studied in older adults. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Lower Respiratory Tract Infection
• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• VXB-251

Snippet

Sponsor: Vicebio Australia Proprietary Limited | Conditions: Lower Respiratory Tract Disease, Healthy Participants | Phase 1 | Status: RECRUITING